Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
Total Valuation
Moleculin Biotech has a market cap or net worth of $8.06M. The enterprise value is -$2.45M.
Market Cap$8.06M
Enterprise Value-$2.45M
Share Statistics
Moleculin Biotech has 2,066,519 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,066,519
Owned by Insiders53.23%
Owned by Institutions―
Financial Efficiency
Moleculin Biotech’s return on equity (ROE) is -3.64 and return on invested capital (ROIC) is -227.97%.
Return on Equity (ROE)-3.64
Return on Assets (ROA)-1.29
Return on Invested Capital (ROIC)-227.97%
Return on Capital Employed (ROCE)-2.30
Revenue Per Employee0.00
Profits Per Employee-1.28M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Moleculin Biotech is ―. Moleculin Biotech’s PEG ratio is 0.12.
PE Ratio―
PS Ratio0.00
PB Ratio24.47
Price to Fair Value24.47
Price to FCF-6.13
Price to Operating Cash Flow-0.44
PEG Ratio0.12
Income Statement
In the last 12 months, Moleculin Biotech had revenue of 0.00 and earned -21.76M in profits. Earnings per share was -158.00.
Revenue0.00
Gross Profit0.00
Operating Income-26.64M
Pretax Income-21.76M
Net Income-21.76M
EBITDA-26.52M
Earnings Per Share (EPS)-158.00
Cash Flow
In the last 12 months, operating cash flow was -22.45M and capital expenditures 0.00, giving a free cash flow of -22.45M billion.
Operating Cash Flow-22.45M
Free Cash Flow-22.45M
Free Cash Flow per Share-10.86
Dividends & Yields
Moleculin Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.57
52-Week Price Change-90.98%
50-Day Moving Average9.67
200-Day Moving Average15.88
Relative Strength Index (RSI)22.79
Average Volume (3m)2.74M
Important Dates
Moleculin Biotech upcoming earnings date is Mar 20, 2026, TBA (Confirmed).
Last Earnings DateNov 17, 2025
Next Earnings DateMar 20, 2026
Ex-Dividend Date―
Financial Position
Moleculin Biotech as a current ratio of 0.97, with Debt / Equity ratio of -1.45%
Current Ratio0.97
Quick Ratio0.97
Debt to Market Cap0.00
Net Debt to EBITDA0.14
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Moleculin Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Moleculin Biotech EV to EBITDA ratio is -5.38, with an EV/FCF ratio of -5.97.
EV to Sales0.00
EV to EBITDA-5.38
EV to Free Cash Flow-5.97
EV to Operating Cash Flow-5.97
Balance Sheet
Moleculin Biotech has $6.70M in cash and marketable securities with $390.00K in debt, giving a net cash position of $6.31M billion.
Cash & Marketable Securities$6.70M
Total Debt$390.00K
Net Cash$6.31M
Net Cash Per Share$3.05
Tangible Book Value Per Share-$1.50
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Moleculin Biotech is $19.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$19.00
Price Target Upside387.18% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast79.31%